UC DAVIS Researchers hone in on Angelman Syndrome Treatment
FAST (Foundation for Angelman Syndrome Therapeutics) has funded two research labs at the University of California, Davis (UC Davis) to further investigation
Towards Therapeutics – The FIRE Team Series, Part II
RDr. Dindot’s 3 goals, which have been the focus of his AS research through the FIRE initiative, are;
Mechanisms regulating imprinting of UBE3A in ne
Towards Therapeutics -The FIRE Team Series, Part IV
Dr Anne Anderson of the FAST FIRE team works on evaluating seizure and behavioral phenotypes (characteristics) in AS mice and how this information can be use
Ketone esters for the treatment of seizures in AS – clinical trial coming soon!
Medical foods as an effective approach to management of Angelman Syndrome The following is a recount of a presentation about using therapeutic ketones (KES)
The FIRE team of FAST turns on Ube3a in mice with Angelman Syndrome….the future gets even MORE promising with Zinc Finger technology.
Read about the recently published paper «Protein Delivery of an Artificial Transcription Factor Restores Widespread Ube3a Expression in an Angelman Syndrome
Gene therapy for the treatment of Angelman Syndrome: Future clinical trials
Agilis Biotherapeutics, LLC Drs. Greg Robinson and Jodi Cook This is gene therapy. A virus (adeno-associated virus=AAV) is used to carry (vector) the UBE
Ovid Therapeutics – OV101 as a potential therapeutic
The Development Of OV101 As A Potential Treatment For The Symptoms Of Angelman Syndrome Ovid Therapeutics: Ovid therapeutics is currently assessing the deve
Summary of FAST 2015 Research Lectures
*Disclaimer: All of the summaries published here are only an interpretation by A. Berent of each lecture. None of these lectures were personally transcribed